

SUPPLEMENTARY TABLE 2. Coverage with influenza, COVID-19, and respiratory syncytial virus (RSV) vaccines among adults,\* by Health and Human Services region — National Immunization Survey-Adult COVID Module, United States, November 9, 2024

HHS Region <sup>†</sup>	Influenza		COVID-19		RSV (adults aged ≥75 years)		RSV (adults aged 60–74 years, increased risk)	
	Cumulative n (unweighted)	% vaccinated (95% CI) <sup>§</sup>	Cumulative n (unweighted)	% vaccinated (95% CI) <sup>§</sup>	Cumulative n (unweighted)	% vaccinated (95% CI) <sup>§</sup>	Cumulative n (unweighted)	% vaccinated (95% CI) <sup>§</sup>
Region 1	13,649	43.4 (39.5–47.3)	11,519	24.8 (21.9–27.7)	8,229	43.5 (38.9–48.1)	1,017	32.6 (25.0–40.2)
Region 2	11,495	33.5 (30.5–36.5)	9,255	15.5 (13.6–17.4)	6,208	31.6 (27.1–36.0)	699	22.9 (16.8–29.1)
Region 3	21,796	39.6 (36.7–42.5)	18,364	20.3 (18.1–22.5)	12,246	41.3 (38.1–44.5)	1,500	30.8 (25.6–36.0)
Region 4	15,948	28.7 (25.5–31.9)	12,832	13.4 (11.1–15.8)	10,613	34.3 (31.4–37.2)	969	35.4 (25.2–45.5)
Region 5	15,425	35.7 (32.1–39.3)	12,546	20.5 (17.9–23.1)	8,453	46.5 (41.0–51.9)	946	35.5 (29.2–41.9)
Region 6	19,958	32.2 (27.9–36.4)	16,318	13.9 (10.7–17.1)	10,597	32.9 (28.9–36.8)	1,248	31.9 (21.4–42.4)
Region 7	5,975	40.1 (33.9–46.4)	4,278	20.1 (15.3–24.8)	3,404	43.0 (36.5–49.5)	322	28.0 (16.4–39.6)
Region 8	14,145	37.0 (30.8–43.3)	12,365	19.1 (14.7–23.5)	8,284	42.7 (38.9–46.5)	983	43.4 (32.2–54.6)
Region 9	11,381	39.2 (33.3–45.1)	9,261	21.7 (17.7–25.8)	7,423	44.4 (36.6–52.2)	642	25.5 (19.2–31.8)
Region 10	6,423	33.0 (27.3–38.7)	5,302	21.6 (17.0–26.1)	4,109	52.7 (38.5–66.8)	341	37.2 (30.9–43.5)

**Abbreviations:** HHS = Department of Health and Human Services; RSV = respiratory syncytial virus.

\* Estimates presented for influenza and COVID-19 vaccination are among adults aged ≥18 years. Estimates for RSV vaccination are among adults aged ≥75 years and aged 60–74 years who are at increased risk for severe RSV disease. Estimates of vaccination coverage were calculated for November 3–9, 2024 using a nondecreasing composite estimation procedure that uses data from all completed interviews during August 18, 2024–November 9, 2024 (Influenza vaccination among persons aged ≥18 years, N = 136,195); September 1, 2024–November 9, 2024 (COVID-19 vaccination among persons aged ≥18 years, N = 112,040); September 24, 2023–November 9, 2024 (RSV vaccination among persons aged ≥75 years, N = 79,566); and August 25, 2024–November 9, 2024 (RSV vaccination among persons aged 60–74 years, at increased risk for severe RSV disease, N = 8,667). A respondent was considered to be at increased risk for severe RSV disease based on the criteria defined in [https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm#B1\\_down](https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm#B1_down): chronic lung diseases, diabetes with insulin use, heart conditions, immunocompromised state, solid organ or blood stem cell transplant (including bone marrow transplant), cancer, liver disease, sickle cell disease or thalassemia, or currently lives in a nursing home.

† HHS Regions: (1) Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; (2) New Jersey, New York, Puerto Rico; (3) Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; (4) Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; (5) Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; (6) Arkansas, Louisiana, New Mexico, Oklahoma, Texas; (7) Iowa, Kansas, Missouri, Nebraska; (8) Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; (9) Arizona, California, Hawaii, Nevada; (10) Alaska, Idaho, Oregon, Washington.

§ Weighted percentage.